To evaluate if urinary continence in patients with refractory neurogenic detrusor overactivity (NDO) incontinence after intradetrusor onabotulinumtoxinA injections is sufficient for appropriate outcome assessment or if urodynamic investigation (UDI) is needed.
Introduction
Neurogenic detrusor overactivity (NDO) frequently causes urinary incontinence (UI) and high storage detrusor pressures [1] . UI can substantially impair patients' healthrelated quality of life [2, 3] , and high storage detrusor pressures can cause irreversible structural changes in the lower urinary tract and present a risk factor for upper urinary tract damage [1, 3] . Therefore, patients with NDO have an increased risk of developing terminal renal failure [4] and renal disease in the past was responsible for almost 50% of deaths in patients with spinal cord injury (SCI) [5] [6] [7] .
Intradetrusor onabotulinumtoxinA injections are a minimally invasive therapy for patients with NDO incontinence refractory to antimuscarinics [1, 8] . Good results for efficacy, safety and improvement in the health-related quality of life led to the regulatory approval of intradetrusor onabotulinumtoxinA injections for treating NDO incontinence [9, 10] , with favourable long-term effects reported [11] [12] [13] . Intradetrusor onabotulinumtoxinA injections are considered the standard second-line treatment [2] and are recommended by all major guidelines [3, 14, 15] .
Urodynamic investigation (UDI) is the 'gold standard' for assessing patients with refractory neurogenic lower urinary tract dysfunction (NLUTD) and it is the only diagnostic tool to measure and quantify detrusor pressures [1, 3] . However, assessments of NDO treatment often consider symptom-based outcomes as key endpoints not considering UDI variables or leaving them, at most, as secondary outcomes [16] . Nevertheless, high storage detrusor pressures can lead to lower and upper urinary tract damage even though NDO treatment may have successfully abolished the associated symptoms.
We therefore aimed to investigate if the attainment of urinary continence in patients with NDO incontinence after intradetrusor onabotulinumtoxinA injections is sufficient for appropriate outcome assessment or if UDI is needed.
Patients and Methods

Patients
From June 2012 to December 2014, a consecutive series of 148 patients treated with intradetrusor onabotulinumtoxinA injections for refractory NDO incontinence, were prospectively evaluated at the Spinal Cord Injury Center, Balgrist University Hospital, Z€ urich, Switzerland. Pregnant and breast feeding women, patients aged <18 years, and patients with predominantly stress UI were excluded. The study was approved by the local ethics committee and is registered with ClinicalTrials.gov (study registration number: NCT01293110). All participants gave written informed consent. All methods, definitions, and units are according to the standards recommended by the ICS [17] .
Neuro-Urological Evaluation and Investigation
All patients underwent neuro-urological assessment [1] and UDI according to good urodynamic practices and following the recommendations of the ICS [18, 19] . The bladder was filled with a body warm mixture of 0.9% NaCl solution and contrast medium at 20-30 mL/min with the patient in a sitting position whenever possible. To address patients' everyday situation, UDI was not routinely stopped after infusion of 500 mL, but maximum bladder filling volume was adapted according to patients' bladder capacity documented in the bladder diary. At 6 weeks after onabotulinumtoxinA treatment, neuro-urological assessment and UDI were repeated.
OnabotulinumtoxinA Treatment
Intradetrusor onabotulinumtoxinA injections (Botox â , Allergan, Inc., Irvine, CA, USA) were routinely performed under local anaesthesia in an outpatient setting as described previously [8] . In brief, lidocaine gel (Instillagel â 2 9 10 mL, Farco-Pharma GmbH, Germany) was instilled into the urethra and exposed for 10 min. Urethro-cystoscopy was performed in a lithotomy or supine position using a rigid or flexible cystoscope in women and men, respectively. Patients received 200 units onabotulinumtoxinA sparing the trigone [8] .
Outcome Measures
The primary outcome measure was the prevalence of maximum storage detrusor pressure (Pdet max storage) of >40 cmH 2 O (6 weeks after treatment) in clinical responders who became continent (defined as completely dry, i.e. no episodes of UI) after intradetrusor onabotulinumtoxinA injections.
The secondary outcome measures were: treatment effects on clinical (urinary frequency/24 h, UI episodes/24 h, number of pads used/24 h) and video-urodynamic variables (maximum cystometric capacity, compliance, Pdet max storage, DO, bladder filling volume at first DO, and vesico-uretero-renal reflux) before and after intradetrusor onabotulinumtoxinA injections. In addition, the influence of clinical variables (gender, underlying neurological disorder, mobility, type of bladder emptying, and numbers of prior intradetrusor onabotulinumtoxinA injections) on treatment success were evaluated.
Statistical Analyses
Data were approximately normally distributed and presented as mean AE standard deviation (SD) or numbers with percentages. For binominal proportions the Wilson CI was calculated. To address the sample size Fisher's exact test was used to test significance of independence for influencing factors on treatment outcomes. Univariate analyses were performed to identify variables, i.e. gender, underlying neurological disorder, Pdet max storage before treatment, mobility, type of bladder emptying, and numbers of prior intradetrusor onabotulinumtoxinA injections, associated with urodynamic response to treatment. Comparing related/ unrelated samples, the paired/unpaired t-test was applied. For comparison of unrelated and related binary data, the chisquared test and McNemar test were used, respectively. Statistical analyses were performed using the IBM Statistical Package for the Social Sciences (SPSS â , version 22; SPSS Inc., IBM Corp., Armonk, NY, USA), with a P < 0.05 considered statistically significant.
Results
Patients' Characteristics
Patients' characteristics are shown in Table 1 . In all, 148 patients were included. The mean (SD) age at enrolment was 54 (18) and 53 (17) years for female and male patients, respectively.
Clinical Evaluation
At 6 weeks after intradetrusor onabotulinumtoxinA injections, 66% (98/148) of the patients with NDO incontinence became continent and 86% (128/148) had a reduction in UI episodes of >50% (Fig. 1) . Changes in urinary frequency, UI episodes, and the number of pads used/24 h are shown in Table 2 .
Video-Urodynamic Investigation
All urodynamic variables improved significantly after treatment compared with before treatment (P ≤ 0.012) ( Table S1 ). Baseline urodynamic variables did not differ significantly (P ≥ 0.1) between continent patients (n = 98) and patients with UI (n = 50) after onabotulinumtoxinA injections ( The comparison of continent patients with a Pdet max storage of ≤40 cmH 2 O (n = 80) vs >40 cmH 2 O (n = 18) after treatment showed significant differences (P < 0.001) in their Pdet max storage before and after onabotulinumtoxinA injections. There was also a significant difference for persistent DO after treatment (50/80 [63%] vs 18/18 [100%], P = 0.002). There was no substantial variation in the other urodynamic variables measured (Table 3) .
In all, 18 of the 148 patients had vesico-uretero-renal reflux before treatment, which persisted in nine (50%) after intradetrusor onabotulinumtoxinA injections. Of these nine patients, five had UI and four were continent; two had persistent high Pdet max storage. These nine patients underwent re-injections with 200 units onabotulinumtoxinA 3 months after the first treatment; re-injections were successful in three and failed in six patients who underwent bladder augmentation (one patient) or cystectomy with ileal conduit (three), two patients did not undergo further treatment on personal request.
Predictors and Influencing Factors
Fisher's exact test revealed a dependency between a Pdet max storage of >40 cmH 2 O and gender (P = 0.02), underlying neurological disorder (P = 0.031), and Pdet max storage before treatment (P < 0.001) ( Table 4 ). However, for complex statistical analysis the number of patients at risk was too low. Mobility (ambulatory or wheelchair), type of bladder emptying (spontaneous voiding, intermittent selfcatheterisation or indwelling catheter), and numbers of prior intradetrusor onabotulinumtoxinA injections did not have a significant impact (P ≥ 0.1) on treatment effects.
Further Treatments
Of the 18 continent patients with a persistent Pdet max storage of >40 cmH 2 O after onabotulinumtoxinA treatment, 56% (10/18) had an adequate clinical and urodynamic response after re-injections with 200 units onabotulinumtoxinA 3 months after the first treatment. The remaining 44% (eight of 18) did not respond with a persistent Pdet max storage of >40 cmH 2 O (Table S2) . Of the eight patients with a persistent Pdet max storage of >40 cmH 2 O, two underwent bladder augmentation and one underwent cystectomy with ileal conduit due to persistent high Pdet max storage and a low-compliance bladder despite several (6-8) 
Discussion
Main Findings
In our present prospective study, including a consecutive series of 148 patients treated with intradetrusor onabotulinumtoxinA injections for refractory NDO incontinence, 66% (98/148) became continent but almost one out of five (18%, 18/98) continent patients had a Pdet max storage of >40 cmH 2 O putting the upper urinary tract at risk. Identified by UDI, another 56% (10/18) of patients achieved a safe Pdet max storage after repeated onabotulinumtoxinA injections. Thus, urinary continence alone is not sufficient for outcome assessment, as high intravesical pressures jeopardising renal function might be missed in a relevant proportion of continent patients. We therefore strongly recommend UDI as a routine part of follow-up after intradetrusor onabotulinumtoxinA injections for refractory NDO incontinence.
Findings in the Context of Existing Evidence
Until 1950,~50% of patients with SCI died from renal failure [4, 7] . Based on a publication by McGuire et al. [20] dating back to 1981, the generally accepted safe limit for Pdet max storage is still 40 cmH 2 O, although there is a complete lack of high-level evidence studies on this topic. Nevertheless, it should be considered that a randomised controlled trial assessing the ideal threshold level for Pdet max storage would raise major ethical concerns.
UDI is the only method that can objectively assess Pdet max storage [1, 3, 19] . Therefore, regular UDIs are relevant for patients with NLUTD, allowing patient-tailored management and urodynamic variables to be kept within safe limits [5] .
Intradetrusor onabotulinumtoxinA injections are a wellestablished and recognised therapeutic option for patients with NDO, leading to significant clinical and urodynamic improvement [9] [10] [11] [12] [13] 21] . The benefits reach their maximum at between 2 and 6 weeks [21, 22] , causing a long-lasting but reversible effect for an average duration of 9 months [3] . The dose with the most acceptable risk-benefit ratio in patients with NDO is 200 units onabotulinumtoxinA [2] . Long-term follow-up studies show good results, indicating that onabotulinumtoxinA is a repeatable treatment with maintained efficacy over years [11] [12] [13] 23] . Although most onabotulinumtoxinA publications refer to urodynamic outcomes, failures are rarely mentioned, leaving limited room to discuss outliers [24, 25] . A systematic review of intradetrusor onabotulinumtoxinA treatment in patients with NDO, including 18 studies, showed an overall positive impact on urodynamic variables, with a mean reduction of Pdet max storage of~40-60% and baseline levels of 60-80 cmH 2 O. Five studies reported a Pdet max storage after treatment of >40 cmH 2 O in the pooled analyses but follow-up examinations and inclusion criteria were not clearly defined [22] . Focusing on pure urodynamic outcomes in patients (n = 691) of two pivotal phase III trials [9, 10] , the effect on Pdet max storage during the first DO up to 12 weeks after therapy was a mean reduction from 29 to 35 cmH 2 O and from 27 to 33 cmH 2 O in patients treated with 200 and 300 units onabotulinumtoxinA, respectively. However, relevant outliers regarding the decrease of Pdet max storage must be assumed, considering the wide SD of AE 36 to 48 cmH 2 O and AE 33 to 38 cmH 2 O in patients treated with 200 and 300 units onabotulinumtoxinA, respectively.
Our present results suggest that gender, underlying neurological disorder, and high Pdet max storage before treatment are potential risk factors for poor urodynamic outcomes after onabotulinumtoxinA therapy. This is consistent with the study by Kuo et al. [26] reporting a significantly better onabotulinumtoxinA effect in patients with SCI than in those with chronic cerebrovascular accident.
Implication for Practice
Combining patients' and physicians' treatment expectations is a challenge, especially as patients' and physicians' values and preferences can differ substantially [27] . In the present study, we found a relevant proportion of patients who were very satisfied with their treatment as they became continent after intradetrusor onabotulinumtoxinA injections, but who had to undergo re-injections because intravesical storage pressure still jeopardised the upper urinary tract. Therefore, all patients with a high storage pressure system and NDO incontinence undergoing intradetrusor onabotulinumtoxinA injections should be informed that UDI as a routine part of the follow-up is strongly recommended and that re-injections might be necessary to protect renal function despite becoming completely continent after treatment. Meeting patients' expectations is related to increased satisfaction and thereby an important indicator of the quality of care [11, 28] . This emphasises the relevance of the informed consent procedure before onabotulinumtoxinA treatment, not only for the potential need of intermittent self-catheterisation [29] [30] [31] and for the risk of treatment discontinuation over time [11] , but also for short-term post-treatment follow-up and reinjections. In addition, more invasive therapies, such as bladder augmentation or cystectomy with continent/ incontinent urinary diversion, should be considered in patients with persistent high Pdet max storage despite several onabotulinumtoxinA treatment cycles [3] .
Implication for Research
Heterogeneity in study designs makes between study comparisons difficult, even in the case of randomised controlled trials. Thus, prospective large-scale multicentre studies are highly warranted to investigate still unanswered questions such as: risk stratification for treatment outcomes; ideal number, depth and site of injections; optimal toxin dosage; time interval between re-injections after unsuccessful treatment; combination with other therapeutic options, such as antimuscarinics and/or neuromodulative procedures; and consideration for more invasive therapies, such as bladder augmentation and urinary diversions. Moreover, research to elucidate the detailed mechanisms of action of intradetrusor onabotulinumtoxinA injections would be essential to improve efficacy and safety, and to establish new application routes.
Limitations of the Study
Some limitations of the present study should be considered. The study was not conducted in a randomised design, but it was prospective and representative of daily clinical practice. It should be taken into account that our unit is a highly specialised university neuro-urology centre, so that negative selection bias (inclusion of more severe cases) cannot be Table 4 Evaluation of patients continent after onabotulinumtoxinA (n = 98) with a Pdet max storage >40 cmH 2 O before (n = 52) and at 6 weeks after treatment (n = 18) according to gender and underlying neurological disorder.
Variable
Pdet max storage >40 cmH 2 O Before onabotulinumtoxinA treatment (n = 52), n/N (%) After onabotulinumtoxinA treatment (n = 18), n/N (%) completely eliminated. Although patients with different underlying neurological disorders were included in the study, almost two-thirds were patients with SCI and sub-group analyses were not possible due to the relatively few non-SCI patients. Finally, a Pdet max storage of >40 cmH 2 O, as a risk factor for upper urinary tract damage, is extrapolated from patients with SCI and spina bifida, even though the incidence of upper urinary tract damage and renal failure is higher in these populations compared to those with slowly progressive non-traumatic neurological disorders such as multiple sclerosis and Parkinson's disease [1] . Although this risk factor is generally agreed by the neuro-urology community, it does emphasise the paucity of non-SCI/non-spina bifida data in this perspective warranting further prospective investigations.
Conclusions
Based on the findings of the present study, urinary continence alone is not sufficient for outcome assessment after intradetrusor onabotulinumtoxinA injections in patients with refractory NDO incontinence, as almost one out of five continent patients had persistent high Pdet max storage putting the upper urinary tract at risk. In patients with NDO incontinence, we therefore strongly recommend UDI as a routine part of the follow-up after intradetrusor onabotulinumtoxinA injections.
